Table 1—

Subject characteristics and effects on CVD risk at the start of the trial and after 3 months of treatment

Placebo
Isoflavones
P for between-treatment differenceP for period effectP for crossover effect
Baseline3 monthsPercent change between baseline and 3 monthsBaseline3 monthsPercent change between baseline and 3 months
BMI (kg/m2)31 ± 6.430.7 ± 5.50.01 (−0.55 to 0.59)30.7 ± 5.530.7 ± 5.50.02 (−0.69 to 0.75)0.970.10.7
Blood pressure (mmHg)
    Systolic133 ± 15137 ± 164.26 (−1.28 to 9.8)130 ± 16129 ± 120.69 (−3.44 to 4.8)0.350.50.9
    Diastolic75 ± 1076 ± 82.79 (−2.99 to 8.57)73 ± 974 ± 9−0.24 (−4.23 to 3.76)0.380.50.7
A1C (%)6.7 ± 0.66.8 ± 0.71.00 (−0.20 to 2.2)6.7 ± 0.76.8 ± 0.61.56 (−0.43 to 3.5)0.580.50.2
Plasma glucose (mmol/l)7.0 ± 1.46.9 ± 1.3−0.34 (−3.6 to 2.9)6.9 ± 1.36.8 ± 1.2−1.6 (−4.3 to 1.13)0.590.10.1
Insulin (μU/ml)14.1 ± 1013 ± 6.9−0.39 (−12 to 11.2)12.8 ± 8.114.1 ± 9.2−13.4 (−27.3 to 0.38)0.150.40.5
HOMA-IR4.6 ± 4.54.5 ± 2.5−4.49 (−15.58 to 6.6)4.03 ± 3.34.5 ± 3.8−15.95 (−31.1 to 0.77)0.240.50.7
Cholesterol (mmol/l)
    Total5.4 ± 15.4 ± 0.92.14 (−7.54 to 3.25)5.4 ± 15.5 ± 0.92.01 (−6.4 to 2.4)0.960.30.9
    LDL3.4 ± 0.93.4 ± 0.83.6 (−10.5 to 3.1)3.4 ± 0.83.5 ± 0.93.85 (−9.9 to 2.2)0.970.20.7
    HDL1.2 ± 0.31.2 ± 0.30.37 (−3.69 to 4.4)1.2 ± 0.31.2 ± 0.30.16 (−3.4 to 3.6)0.930.80.4
Triglycerides (mmol/l)1.8 ± 0.81.7 ± 0.7−4.16 (−16.2 to −7.9)1.9 ± 0.91.8 ± 0.9−1.19 (−13,3 to 10.9)0.740.80.2
CRP (mg/l)5.1 ± 6.76.4 ± 10.124.4 (−46.5 to 2.21)5.4 ± 86.2 ± 844 (−43.5 to 133)0.400.30.4
  • Data are means ± SD or means(95% CI). The percentages of change in each group were comparedto obtain the P values for the between-treatment difference. CRP, C-reactive protein.